tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
US Market

Inhibikase Therapeutics (IKT) Ownership - Who Owns Inhibikase Therapeutics?

Compare
168 Followers

Inhibikase Therapeutics (IKT) Ownership Overview

10.53%0.13%66.08%3.98%19.29%
10.53% Insiders
66.08% Other Institutional Investors
3.98% ETFs
19.29% Public Companies and Individual Investors
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 70.18% of the company’s stock is owned by Institutional Investors, 10.53% is owned by Insiders, and 19.29% is owned by Public Companies and Individual Investors.
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 66.20% of the company’s stock is owned by Institutional Investors, 10.53% is owned by Insiders, and 3.98% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 23, 2024
Amit Munshi
Director
xxxxxxxxxxxxx
$500050
Oct 23, 2024
xxxxxxxxxxxxx
$2000200
Oct 23, 2024
Kush Arvind
Director
xxxxxxxxxxxxx
$198650

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
5,335,433Insider7.69%12,538,268
2,760,750Institution3.98%6,487,763
1,460,000Insider2.10%3,431,000
365,000Insider0.53%857,750
145,000Insider0.21%340,750
59,477Institution0.09%139,771
16,724Institution0.02%39,301
11,000Institution0.02%25,850

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
59,477Institution0.09%139,771
16,724Institution0.02%39,301
11,000Institution0.02%25,850

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,277,400Institution3.28%7,401,550
483,350Institution0.70%1,570,888

FAQ

Who Owns Inhibikase Therapeutics (IKT)?
According to the latest TipRanks data, approximately 66.08% of the company's stock is held by institutional investors, 10.53% is held by insiders, and 19.29% is held by retail investors.
    What percentage of Inhibikase Therapeutics (IKT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 66.08% of Inhibikase Therapeutics (IKT) stock is held by institutional investors.
      What percentage of Inhibikase Therapeutics (IKT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 19.29% of Inhibikase Therapeutics (IKT) stock is held by retail investors.
        Who owns the most shares of Inhibikase Therapeutics (IKT)?
        Milton H. Werner owns the most shares of Inhibikase Therapeutics (IKT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis